Castleview Partners’s Axcelis ACLS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q1
Sell
-230
Closed -$16.1K 180
2024
Q4
$16.1K Hold
230
0.01% 503
2024
Q3
$24.1K Hold
230
0.01% 421
2024
Q2
$32.7K Hold
230
0.02% 379
2024
Q1
$25.6K Buy
230
+70
+44% +$8.34K 0.01% 434
2023
Q4
$20.8K Buy
160
+130
+433% +$17.9K 0.01% 432
2023
Q3
$4.89K Buy
+30
New +$5.28K ﹤0.01% 489

Other funds holding ACLS

Castleview Partners's ACLS Position: Q1 2025 in Review

Castleview Partners sold out of Axcelis (ACLS) in Q1 2025, closing a stake of 230 shares — an estimated $16.1K sold.

Castleview Partners first reported a position in ACLS in Q3 2023 and held it in 6 quarters. The position peaked at $32.7K in Q2 2024. 306 funds tracked by Wall St. Rank hold ACLS as of Q1 2025.

  • Castleview Partners reported no remaining Axcelis position as of Q1 2025 after selling out during the quarter.
  • Castleview Partners sold 230 Axcelis shares in Q1 2025, an estimated $16.1K.
  • Castleview Partners first reported a position in Axcelis in Q3 2023 and held it in 6 quarters.
  • Castleview Partners's Axcelis position peaked at $32.7K in Q2 2024.
  • 306 funds tracked by Wall St. Rank held Axcelis as of Q1 2025.

Based on Castleview Partners's 13F filing for Q1 2025, filed 22 Apr 2025.